P
Paul Nathan
Researcher at Northwood University
Publications - 213
Citations - 17048
Paul Nathan is an academic researcher from Northwood University. The author has contributed to research in topics: Melanoma & Trametinib. The author has an hindex of 44, co-authored 181 publications receiving 13804 citations. Previous affiliations of Paul Nathan include John Radcliffe Hospital & Aix-Marseille University.
Papers
More filters
Journal ArticleDOI
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
Grant A. McArthur,Michele Maio,Ana Arance,Paul Nathan,Christian U. Blank,Marie-Françoise Avril,Claus Garbe,Axel Hauschild,Dirk Schadendorf,Omid Hamid,Michael Fluck,M. Thebeau,Jacob Schachter,Richard F. Kefford,M. Chamberlain,Martina Makrutzki,Susan Robson,Rene Gonzalez,Kim Margolin +18 more
TL;DR: The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib, which was well tolerated and without significant CNS toxicity, as well as similar in type, grade and frequency to other studies of single-agent vemurAFenib.
Journal ArticleDOI
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
David Cella,Viktor Grünwald,Bernard Escudier,Hans J. Hammers,Saby George,Paul Nathan,Marc-Oliver Grimm,Brian I. Rini,Justin Doan,Cristina Ivanescu,Jean Paty,Sabeen Mekan,Robert J. Motzer +12 more
TL;DR: This study aimed to assess whether health-related quality of life (HRQoL) could be used to further describe the benefit-risk profile of nivolumab plus ipilimumab versus sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma.
Journal ArticleDOI
Revised UK guidelines for the management of cutaneous melanoma 2010
J. Marsden,Julia Newton-Bishop,L. Burrows,Martin G. Cook,Pippa Corrie,Neil H. Cox,Martin Gore,Paul Lorigan,R.M. Mackie,Paul Nathan,H Peach,Barry Powell,Christy Walker +12 more
TL;DR: The guidelines for the management of cutaneous melanoma presented in this article present an evidence-based guidance for treatment with identification of the strength of evidence available at the time of preparation of the guidelines, and a brief overview of epidemiology, diagnosis, investigation, and follow-up.
Journal ArticleDOI
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
Antoni Ribas,Marcus O. Butler,Jose Lutzky,Donald P. Lawrence,Caroline Robert,Wilson H. Miller,Gerald P. Linette,Paolo A. Ascierto,Timothy M. Kuzel,Alain Algazi,Michael A. Postow,Paul Nathan,Brendan D. Curti,Paul B. Robbins,Xia Li,John A. Blake-Haskins,Michael S. Gordon +16 more
TL;DR: Inhibition of the MAPK pathway with dabrafenib and trametinib is efficacious in BRAf-mutant melanoma and MEK inhibitors have also shown activity in BRAF WT melanoma.
Journal ArticleDOI
Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
Paul Nathan,Martin Zweifel,Anwar R. Padhani,Dow-Mu Koh,Matthew Ng,David J. Collins,Adrian L. Harris,Craig P. Carden,Jon Smythe,Nita Fisher,N. Jane Taylor,J. James Stirling,Shiao-Ping Lu,Martin O. Leach,Gordon J. S. Rustin,Ian Judson +15 more
TL;DR: CA4P in combination with bevacizumab appears safe and well tolerated in this dosing schedule, and DCE-MRI showed statistically significant reductions in tumor perfusion/vascular permeability, which reversed after CA4P alone but which were sustained following bevacsumab.